Topic
KRAS mutations
Pancreatic cancer vaccine shows safety and durable immune response in trial
A phase I trial shows the mKRAS-VAX vaccine can stimulate long-term T-cell responses in individuals with precancerous pancreatic lesions and is well tolerated.